Wantai Bio extends HPV vaccine project, completes diagnostics base

Beijing Wantai Biological Pharmacy Enterprise has decided to extend the "Nine-valent HPV Vaccine Phase II Expansion Project" by one year, with the new target completion date set for December 2026. This extension, approved by the board, aims to ensure project quality and efficient use of funds, with no changes to the project's scope, location, or investment. As of November 30, 2025, the project had seen 61.87% of its adjusted planned investment of 106,015.57 yuan.

Concurrently, the "YangShengTang Xiamen Wantai Diagnostics Base Project," which had an original planned investment of 110,000.00 yuan, has been officially concluded. The project's main construction is complete and has passed quality inspections. As of November 30, 2025, 71,186.14 yuan had been invested in this project, representing a 64.71% progress rate. The remaining funds will be used to cover outstanding payments and operating capital.

The company's non-public offering in 2022 raised net proceeds of 3,460,155,714.17 yuan. While the HPV vaccine project's timeline is adjusted, the Xiamen diagnostics base project has met its operational goals, reflecting the company's strategic project management.